[Effect of cefminox on severe infections accompanying hematological diseases].
A new antibiotic cefminox (CMNX, MT-141) was administered to 54 patients with severe infections accompanying various hematological diseases. The rate of effectiveness was 55.3% on the whole. Mild liver dysfunction was observed in 3 cases, which recovered quickly following the stop of the administration.
D000328:Adult; D000368:Aged; D001424:Bacterial Infections / Q000150:complications / Q000188:drug therapy*; D002513:Cephamycins / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007938:Leukemia / Q000150:complications*; D008223:Lymphoma / Q000150:complications*; D008297:Male; D008875:Middle Aged; D011014:Pneumonia / Q000150:complications / Q000188:drug therapy; D018805:Sepsis / Q000150:complications / Q000188:drug therapy
D002513:Cephamycins; C046079:cefminox